289 related articles for article (PubMed ID: 26830968)
1. TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.
Kalanaky S; Hafizi M; Safari S; Mousavizadeh K; Kabiri M; Farsinejad A; Fakharzadeh S; Nazaran MH
Int J Hematol; 2016 Mar; 103(3):274-82. PubMed ID: 26830968
[TBL] [Abstract][Full Text] [Related]
2. Renal clearable nanochelators for iron overload therapy.
Kang H; Han M; Xue J; Baek Y; Chang J; Hu S; Nam H; Jo MJ; El Fakhri G; Hutchens MP; Choi HS; Kim J
Nat Commun; 2019 Nov; 10(1):5134. PubMed ID: 31723130
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
4. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation in chemotherapy.
Weinberg ED
Adv Appl Microbiol; 2003; 52():187-208. PubMed ID: 12964245
[No Abstract] [Full Text] [Related]
6. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
7. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
8. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
9. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
10. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
11. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Sripetchwandee J; Wongjaikam S; Krintratun W; Chattipakorn N; Chattipakorn SC
Neuroscience; 2016 Sep; 332():191-202. PubMed ID: 27403880
[TBL] [Abstract][Full Text] [Related]
12. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Emara AM; El Kelany RS; Moustafa KA
Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
[TBL] [Abstract][Full Text] [Related]
14. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
15. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Porter JB; Shah FT
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
17. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
18. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
19. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
20. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]